1296 related articles for article (PubMed ID: 22540236)
1. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
2. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
3. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
[TBL] [Abstract][Full Text] [Related]
5. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathological outcomes for a single microfocal (≤3 mm) Gleason 6 prostate cancer detected via contemporary multicore (≥12) biopsy in men with prostate-specific antigen ≤10 ng/mL.
Hong SK; Na W; Park JM; Byun SS; Oh JJ; Nam JS; Jeong CW; Choe G; Lee HJ; Hwang SI; Lee SE
BJU Int; 2011 Oct; 108(7):1101-5. PubMed ID: 21199287
[TBL] [Abstract][Full Text] [Related]
7. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
8. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
9. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
10. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
11. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
[TBL] [Abstract][Full Text] [Related]
12. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
13. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
15. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
[TBL] [Abstract][Full Text] [Related]
17. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
18. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
19. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
20. Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer.
Komai Y; Kawakami S; Numao N; Fujii Y; Saito K; Kubo Y; Koga F; Kumagai J; Yamamoto S; Yonese J; Ishikawa Y; Fukui I; Kihara K
BJU Int; 2012 Dec; 110(11 Pt B):E564-9. PubMed ID: 22757686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
